Literature DB >> 31970171

Application of multiple Roux-en-Y hepaticojejunostomy reconstruction by formation of bile hilar duct lake in the operation of hilar cholangiocarcinoma.

Xiao-Jun Yang1, Xiao-Hua Dong1, Shi-Yong Chen2, Biao Wu2, Yu He3, Bao-Long Dong3, Bing-Qiang Ma1, Peng Gao4.   

Abstract

BACKGROUND: Hilar cholangiocarcinoma is the most common malignant tumor of the extrahepatic bile duct. Until now, radical resection has been the most effective method for the long-term survival of patients with the disease. However, many problems have emerged in the field of hepatobiliary surgery for a long time, including complex surgical procedures, low resection rate, and postoperative complications. We have adopted the "multiple Roux-en-Y hepaticojejunostomy reconstruction by formation of a bile duct lake" technique in the treatment of hilar cholangiocarcinoma since 2008, and obtained satisfactory short- and long-term results. AIM: To examine the feasibility of the application of multiple Roux-en-Y hepaticojejunostomy reconstruction by formation of a bile duct lake in the operation of hilar cholangiocarcinoma.
METHODS: A retrospective analysis was performed for the clinical data, surgical methods, and results of 76 patients with hilar cholangiocarcinoma who were treated with hilar bile duct lake-forming multiple Roux-en-Y hepaticojejunostomy reconstruction at Gansu Provincial Hospital.
RESULTS: In all 76 cases, the operation was successful and no operative death occurred. The mean (range) operation time was 215.4 ± 53.5 min (124-678 min), and the amount of bleeding during the operation was 428.2 ± 63.8 mL (240-2200 mL). The overall 1-year survival rate was 78.9%, and the 3-year survival rate was 32.8%.
CONCLUSION: The multiple Roux-en-Y hepaticojejunostomy reconstruction technique with formation of a bile duct lake is safe and effective for the surgical treatment of hilar cholangiocarcinoma. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Bile duct lake; Hepaticojejunostomy; Hilar cholangiocarcinoma

Year:  2020        PMID: 31970171      PMCID: PMC6962072          DOI: 10.12998/wjcc.v8.i1.68

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  6 in total

1.  Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not?

Authors:  Masaru Miyazaki; Atsushi Kato; Hiroshi Ito; Fumio Kimura; Hiroaki Shimizu; Masayuki Ohtsuka; Hiroyuki Yoshidome; Hideyuki Yoshitomi; Katsunori Furukawa; Satoshi Nozawa
Journal:  Surgery       Date:  2007-03-23       Impact factor: 3.982

2.  [Clinical value of "Kou mode of hepatic hilar anastomosis" in resection of type III or IV hepatic hilar cholangiocarcinoma].

Authors:  Xiao-dong He; Wei Liu; Lian-yuan Tao; Zhen-huan Zhang; Lei Cai; Shuang-min Zhang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2009-08

3.  Does portal vein resection with hepatectomy improve survival in locally advanced hilar cholangiocarcinoma?

Authors:  Gi-Won Song; Sung-Gyu Lee; Shin Hwang; Ki-Hun Kim; Yong-Pil Cho; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha
Journal:  Hepatogastroenterology       Date:  2009 Jul-Aug

4.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

5.  Radical surgery of left-sided klatskin tumors.

Authors:  Y Nimura
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

6.  Surgical treatment of hilar cholangiocarcinoma in the "new era": the Nagoya University experience.

Authors:  Tsuyoshi Igami; Hideki Nishio; Tomoki Ebata; Yukihiro Yokoyama; Gen Sugawara; Yuji Nimura; Masato Nagino
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-10-06       Impact factor: 7.027

  6 in total
  2 in total

1.  NTCP Change in Rats of Hilar Cholangiocarcinoma and Therapeutic Significance.

Authors:  Meng-Yu Zhang; Ming Luo; Kai He; Xian-Ming Xia; Jie-Ping Wang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

2.  FXR expression in rats of hilar cholangiocarcinoma.

Authors:  Meng-Yu Zhang; Ming Luo; Jie-Ping Wang
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.